#37
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
💚 This recent coverage questioning cannabis benefits aligns with growing clinical evidence that therapeutic claims often outpace rigorous data, particularly for mental health and chronic pain indications where placebo effects and publication bias may inflate perceived efficacy. Healthcare providers should recognize that while some cannabinoid formulations (notably CBD-dominant products and dronabinol for specific indications) have established safety and efficacy profiles, the broader medical cannabis landscape remains characterized by limited randomized controlled trials, heterogeneous plant-derived products with variable cannabinoid content, and patients self-selecting for use based on anecdotal reports rather than clinical evidence. The gap between popular perception and clinical evidence is complicated further by legal restrictions that historically limited research, inconsistent state regulations, and difficulty conducting rigorous studies on federally scheduled substances. Clinicians should approach cannabis discussions with patients by acknowledging this evidence uncertainty, screening carefully for potential harms (including cannabis use disorder, cognitive effects, and
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
